Abstract Aim: Inhibition of cyclooxygenase-2 (COX-2) is proposed as a treatment option in
several cancer types. However, in non-small cell lung cancer (NSCLC), phase III trials have …

Background Increased expression of cyclooxygenase-2 (COX-2) is common in non-small
cell lung cancer (NSCLC) and has been associated with poor prognosis. Experimental and …

Purpose Cyclooxygenase-2 (COX-2) protein expression in patients with non–small-cell lung
cancer (NSCLC) may be not only a prognostic marker but also predictive for COX-2 …

8005 Background: Cox-2 is overexpressed in NSCLC tumors and has a negative impact on
survival. It is involved in proliferation and angiogenesis. The hypothesis is that celecoxib by …

Aims Clinical trials have reported conflicting results about whether celecoxib plus
chemotherapy improves outcomes over chemotherapy alone in patients with advanced non …

Purpose Tumor overexpression of cyclooxygenase-2 (COX-2) has been associated with
worse outcome in non–small-cell lung cancer (NSCLC). In Cancer and Leukemia Group B …

© Translational lung cancer research. All rights reserved. Transl Lung Cancer Res 2018; 7
(Suppl 3): S191-S194 tlcr. amegroups. com and retrospective trials (of a total of 2,651 …

Abstract Purpose: Cyclooxygenase (COX)-2 up-regulation plays an important role in the
pathogenesis of lung cancer. Selective COX-2 inhibitors have promoted chemosensitivity …

Background: Studies have reported that advanced NSCLC benefits from celecoxib
combined with systematic treatment. However, the optimal combination with different …

Accumulating preclinical and clinical studies have shown that cyclooxygenase-2 (COX-2)
inhibitor has some efficacy for non-small cell lung cancer (NSCLC). However, two phase III …